You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Details for Patent: 5,736,541


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,736,541
Title: Olanzapine polymorph crystal form
Abstract:The invention provides Form II, a pharmaceutically elegant, stable polymorph of olanzapine useful for treating a condition selected from the group consisting of a psychotic condition, mild anxiety and gastrointestinal conditions.
Inventor(s): Bunnell; Charles Arthur (Lafayette, IN), Hendriksen; Barry Arnold (Guildford, GB), Larsen; Samuel Dean (West Lafayette, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN) Eli Lilly and Company (Basingstoke, GB2)
Application Number:08/686,989
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Process; Use;
Patent landscape, scope, and claims:

United States Patent 5,736,541: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 5,736,541, titled "Olanzapine polymorph crystal form," is a significant patent in the pharmaceutical industry, particularly in the development and commercialization of olanzapine, a medication used to treat various psychiatric conditions. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Background of Olanzapine

Olanzapine is an antipsychotic medication widely used for treating conditions such as schizophrenia, bipolar disorder, and mild anxiety. The drug has shown great promise in managing psychotic symptoms, making it a crucial component in psychiatric treatment regimens[1].

The Invention: Form II of Olanzapine

The patent describes the discovery and characterization of a new polymorph of olanzapine, designated as Form II. This form is distinct from the previously known Form I, which was found to be metastable and not suitable for commercial pharmaceutical use due to its undesirable color and instability[1].

Key Characteristics of Form II

  • Stability and Purity: Form II is stable, pharmaceutically elegant, and can be obtained in highly pure form, free from contamination by solvates such as water or acetonitrile[1].
  • Pharmaceutical Formulations: Form II is well-suited for use in pharmaceutical formulations like tablets, associated with one or more pharmaceutical acceptable excipients[1].
  • Analytical Methods: The characterization of Form II involves various analytical methods, including x-ray powder diffraction, thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), and H¹-NMR analysis[1].

Claims of the Patent

The patent includes several key claims:

  • Polymorph Form II: The patent claims the novel polymorph Form II of olanzapine, which is stable and free from contaminants[1].
  • Pharmaceutical Formulations: Claims include pharmaceutical formulations such as tablets containing Form II as the active ingredient[1].
  • Methods of Use: The patent also claims methods for using Form II in treating psychotic conditions, mild anxiety, and gastrointestinal conditions[1].

Patent Scope

The scope of the patent is defined by its claims and the specific characteristics of Form II. Here are some key aspects:

  • Novelty: The patent introduces a new polymorph of olanzapine that is more stable and suitable for commercial use compared to the earlier Form I[1].
  • Non-Obviousness: The discovery of Form II and its specific preparation methods distinguish it from prior art, making it non-obvious to those skilled in the art[1].

Patent Landscape

Related Patents

The patent landscape surrounding US 5,736,541 includes several related patents:

  • U.S. Pat. No. 5,229,382 ('382 patent): This patent describes the initial preparation methods for olanzapine, which resulted in the metastable Form I[1].
  • Other Olanzapine Patents: Patents such as U.S. Pat. No. 5,627,178, 5,817,655, 5,817,656, and 5,919,485 also relate to different aspects of olanzapine, including other polymorphs, salts, and methods of use[2].

Generic Approvals

The expiration of key patents, including US 5,736,541, has allowed generic manufacturers to enter the market. For example, Apotex Inc. received FDA approval for their generic olanzapine tablets after certifying that their product did not infringe on the remaining patents or that those patents were invalid or unenforceable[2].

Impact on Pharmaceutical Industry

The discovery and commercialization of Form II of olanzapine have had a significant impact on the pharmaceutical industry:

  • Improved Stability: The stability of Form II has enhanced the shelf life and reliability of olanzapine formulations, making it a preferred choice for manufacturers[1].
  • Compliance with Regulatory Standards: The pharmaceutical formulations containing Form II meet stringent regulatory standards, ensuring safety and efficacy for patients[2].

Challenges and Controversies

Patent Quality and Scope

The broader debate on patent quality and scope is relevant here. Critics argue that some patents, including those in the pharmaceutical sector, may have overly broad claims or lack clarity, which can impede innovation and increase litigation costs[3].

Generic Competition

The entry of generic competitors has changed the market dynamics for olanzapine. Generic manufacturers must navigate the complex patent landscape to ensure their products do not infringe on existing patents, as seen in the case of Apotex Inc.[2].

Conclusion

United States Patent 5,736,541 is a pivotal patent in the development of olanzapine, offering a stable and pharmaceutically elegant polymorph suitable for commercial use. The patent's scope and claims are well-defined, contributing significantly to the pharmaceutical industry. However, the broader patent landscape and the challenges associated with patent quality and generic competition highlight the complexities involved in bringing such innovations to market.

Key Takeaways

  • Stable Polymorph: Form II of olanzapine is a stable and pure polymorph suitable for commercial pharmaceutical use.
  • Pharmaceutical Formulations: Form II is used in various pharmaceutical formulations, including tablets.
  • Regulatory Compliance: The patent ensures compliance with regulatory standards for safety and efficacy.
  • Patent Landscape: The patent is part of a complex landscape involving multiple related patents and generic approvals.
  • Industry Impact: The discovery of Form II has significantly improved the stability and reliability of olanzapine formulations.

Frequently Asked Questions (FAQs)

What is the main difference between Form I and Form II of olanzapine?

Form II is a stable and pharmaceutically elegant polymorph, unlike Form I, which is metastable and not well-suited for commercial use due to its instability and undesirable color[1].

How is Form II characterized?

Form II is characterized using various analytical methods, including x-ray powder diffraction, thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), and H¹-NMR analysis[1].

What are the key claims of US 5,736,541?

The patent claims include the novel polymorph Form II, pharmaceutical formulations containing Form II, and methods for using Form II in treating various conditions[1].

Why is the stability of Form II important?

The stability of Form II enhances the shelf life and reliability of olanzapine formulations, making it a preferred choice for manufacturers and ensuring consistent efficacy for patients[1].

How has the expiration of this patent affected the market?

The expiration of this patent has allowed generic manufacturers to enter the market, increasing competition and potentially reducing the cost of olanzapine for consumers[2].

Cited Sources

  1. US5736541A - Olanzapine polymorph crystal form - Google Patents
  2. Olanzapine Tablets USP, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg - FDA
  3. Patent Claims and Patent Scope - Hoover Institution

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 5,736,541

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
No data available in table
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 0 to 0 of 0 entries

International Family Members for US Patent 5,736,541

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
African Regional IP Organization (ARIPO) 828 ⤷  Subscribe
African Regional IP Organization (ARIPO) 9701065 ⤷  Subscribe
Argentina 002719 ⤷  Subscribe
Argentina 002721 ⤷  Subscribe
Argentina 004169 ⤷  Subscribe
Argentina 010448 ⤷  Subscribe
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 6 of 6 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.